28. Systemic amyloidosis
212 clinical trials,   234 drugs   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways

Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002231-18-GB
(EUCTR)
01/12/201523/09/2015A Phase I/IIa (early phase) Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL AmyloidosisA Phase I/IIa Study of Targeted Radiotherapy alone for Stem Cell Transplant Conditioning in Systemic AL Amyloidosis - Targeted Radiotherapy for AL-Amyloidosis –‘TRALA’ AL-Amyloidosis
MedDRA version: 18.0;Level: LLT;Classification code 10024460;Term: Light chain disease myeloma associated;System Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Product Name: CHX-A-DTPA-Anti-CD66
INN or Proposed INN: CHX A-DTPA anti-CD66 antibody
Product Name: Indium­ 111 ­labelled Anti­-CD66
INN or Proposed INN: Indium 111-radiolabelled anti-CD66
Product Name: yttrium-90 radiolabelled anti-CD66 antibody
INN or Proposed INN: Yttrium­90 radiolabelled anti­CD66
University Southampton Hospital NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 1;Phase 2aUnited Kingdom